Fulvestrant

Drug Overview:

Fulvestrant is a potent estrogen inhibitor drug used in the treatment of breast cancer in advanced stages. The Food and Drug Administration (FDA) approved Fulvestrant as a single-agent therapy (monotherapy) in the treatment of breast cancer for postmenopausal women.

Fulvestrant is an estrogen receptor antagonist or inhibitor available in injectable doses of 250 mg (milligrams) and 500 mg. Fulvestrant 500 mg is administered intramuscularly (IM) on days 1, 15, and 29 and then once per month in the gluteal (buttocks) region.

Fulvestrant is used either as a single-agent treatment or in combination therapy with other medicines like Palbociclib or Ribociclib for managing hormone blockers for breast cancer in postmenopausal women.

How Does Fulvestrant Work?

Fulvestrant works by binding to breast cancer receptors and inhibiting tumor growth by blocking and degrading the receptors responsible for tumor growth. This hormone suppression mechanism is aimed at addressing the biological processes that commonly lead to tumor formation in HR-positive breast cancers.

What Is Fulvestrant Used For?

• Fulvestrant is used as monotherapy, or single-agent therapy, for breast cancer treatment in postmenopausal women.

• It can also be used in combination therapy with drugs like Ribociclib and Palbociclib for the management of breast cancer in advanced stages, where there is metastasis.

Doses:

• For Single Agent Therapy: Fulvestrant hormone shots (injections) of 500 mg are to be given intramuscularly (IM) as two 5 ml injections on days 1, 15, and 29, and once per month in the gluteal region. Fulvestrant injection of 250 mg is also used intramuscularly, such as one 5 ml injection on days 1, 15, and 29, and once per month in patients who are systemically compromised. Single-agent therapy, or monotherapy, is recommended in patients with hormone-receptor (HR) positive and HER2 (hormone estrogen receptor) negative tumors with no history of endocrine therapy.

• For Combination Therapy: Fulvestrant hormone shot (injection) of 500 mg is injected intramuscularly, similar to the single agent therapy technique. It is given in combination with other drugs like Palbociclib, which is given orally at a dose of 125 mg once daily for twenty-one days.

• Fulvestrant injection of 500 mg is also given in combination with Ribociclib, which is given at a dose of 600 mg orally for 21 days.

• The combination therapy is usually recommended by doctors for patients who are HR-positive (metastatic cancer), HER2 (hormone estrogen receptor), a negative cancer that has progressed to the advanced stage due to a history of endocrine therapy.

Warning:

• Risk of Bleeding: As the drug is administered through an intramuscular (IM) route, there is a risk of bleeding. Cautions should be taken while administering this drug to patients with bleeding disorders and patients who are on anticoagulant or blood-thinning medications.

• Hepatic Impairment: Liver impairment has been reported in a few patients. The drug Fulvestrant, in a dose of 250 mg, is prescribed for such patients.

• Fetal Toxicity: Few clinical studies have reported harm to the fetus when the drug is administered to pregnant females.

For Patients:

What Do You Need to Know About Postmenopausal Breast Cancer?

After menopause, your risk of breast cancer can increase. This is more common after the age of 55. One reason for this is changes in estrogen levels in your body. Estrogen is a hormone that helps control the growth of breast and uterine tissue. After menopause, shifts in how your body handles estrogen may affect your breast cancer risk.

If you take hormone therapy (HT) after menopause, your risk may be higher. That’s why it’s important to talk with your doctor about the benefits and possible side effects before starting any hormonal treatment.

Your body weight can also play a role. If you are overweight or obese, your risk of breast cancer may increase because fat tissue can produce estrogen even after menopause.

The most important step is communication. Before starting hormone therapy, or if you have concerns about your risk, talk openly with your doctor. Together, you can decide what is safest and best for you.

How Can We Reduce the Risk of Breast Cancer After Menopause?

A few minor changes in your daily lifestyle can reduce the risk of breast cancer.

Some changes that need to be inculcated are:

• Exercise daily.

• Have a balanced diet.

• Avoid smoking and consuming alcohol.

• Avoid gaining unnecessary weight by monitoring your body mass index (BMI).

• Reduce the number of doses of hormonal therapy.

• In the case of females with a family history of breast cancer, it is recommended to undergo breast screening programs and mammography to detect any precancerous breast conditions.

• Preventive breast cancer medications like hormone blockers for breast cancer (estrogen blockers) can be taken under the prescription of a doctor in the case of females who are suspected of having an increased risk of breast cancer.

• Preventive surgical management, like prophylactic mastectomy (removal of all breast tissue), is recommended by doctors for women who are at heightened risk of getting breast cancer based on the symptoms.

Is Hormonal Therapy Safe?

The hormonal therapy used after menopause increases the risk of cancer tremendously. It is always better to discuss the benefits and the side effects of hormonal therapy (estrogen and progesterone) with your doctor before initiating the therapy.

What Are the Causes of Breast Cancer?

One of the following risk factors can increase the chances of breast cancer:

• Hormonal changes (a sudden increase in estrogen and progesterone levels after menopause).

• Unhealthy lifestyle.

• Chronic smoking.

• Excessive alcohol and caffeine intake.

• Hereditary - family history of breast cancer.

• Obesity.

• Radiation exposure.

• Menopause starts at an older age.

• Women having their first child after the age of 30 are more likely to get breast cancer.

• Women with no history of pregnancy are at greater risk of breast cancer compared to women with multiple pregnancies.

• Hormonal therapy - Women who undergo hormonal therapy (HT) after menopause are at increased risk.

Learn More About Fulvestrant:

What Is Fulvestrant?

Fulvestrant is a type of hormone therapy used to treat certain kinds of breast cancer. If your cancer is affected by estrogen, this medicine may be an option for you.

Fulvestrant works by blocking estrogen receptors on breast cancer cells. When estrogen can’t attach to these receptors, the cancer cells grow more slowly.

The Food and Drug Administration approved Fulvestrant in 2002. Studies showed that people taking Fulvestrant took longer for their cancer to worsen compared to those taking another hormone therapy medicine called anastrozole.

Fulvestrant is approved only for specific types of breast cancer in women. Your doctor will prescribe it only if it is likely to work for your condition.

You receive Fulvestrant as an injection into the buttock muscle, usually once a month. Your doctor may adjust the dose based on how well it works for you and how your body responds.

In some cases, your doctor may combine Fulvestrant with other breast cancer medicines to improve treatment results. Your care team will explain why this approach may be right for you.

When and Why to Take Fulvestrant Medication?

If you are a woman diagnosed with postmenopausal breast cancer, your doctor may prescribe Fulvestrant based on your symptoms and test results. These symptoms can include frequent headaches, hot flashes, mood swings, or findings from breast screening and mammography. Fulvestrant works by reducing excessive estrogen levels in your body. This can help slow the growth of your breast cancer and may also ease some postmenopausal symptoms.

Clinical trials on fulvestrant have demonstrated its effectiveness in women with advanced breast cancer, including cases where the cancer has spread to other parts of the body (distant metastasis).

The medicine can be used on its own (monotherapy) or in combination with other drugs, like Palbociclib. Your doctor will discuss the best treatment and how your body responds to treatment.

Why Is Fulvestrant Prescribed?

If you are postmenopausal and your breast cancer cells are estrogen receptor (ER) positive, your doctor may prescribe Fulvestrant. Clinical trials have shown that Fulvestrant can lower estrogen levels in your body. This helps reduce symptoms related to postmenopausal breast cancer, such as hot flashes, mood swings, or other hormone-related changes.

For women with localized breast cancer, Fulvestrant has been shown to slow the progression of the disease, with noticeable effects within about 21 months of treatment.

It may also help women with metastatic breast cancer by improving the overall management of the disease.

What Fulvestrant Precautions Should I Follow?

• Inform your doctor if you have any history of allergies to any medications.

• Inform your doctor if you have any systemic medical conditions like diabetes, liver diseases, or bleeding disorders like hemophilia and bleeding diathesis.

• Inform your doctor if you are taking any medications, such as blood thinners or anticoagulants like Warfarin.

• Any habits like alcohol and smoking should be disclosed to the doctor.

• Women who are planning pregnancy, breastfeeding mothers, or pregnant women should inform their doctor about their respective health status.

Starting Fulvestrant Medications:

How Should I Use Fulvestrant?

Fulvestrant should be taken as prescribed by the doctor, at the prescribed dose and frequency.

Fulvestrant is available as an injection at 250 mg per 5 mL vial; two vials are required for the 500 mg dose.

It is given intramuscularly by a doctor or nurse, slowly, into the gluteal region (buttocks). It is prescribed once every two weeks.

The first three doses are given on days 1, 15, and 29. After that, it is administered once a month.

Things to Do After You Start Taking Fulvestrant

• Inform your doctor if you experience any Fulvestrant side effects, such as swelling at the injection site, swollen feet or ankles, shortness of breath, or chest pain.

• Check for the improvement in the symptoms and keep track of them.

• Inform the doctor about the improvement in the symptoms noticed during the follow-up sessions.

What Are the Side Effects of Fulvestrant?

The common Fulvestrant side effects include:

• Pain and redness at the injection site.

• Nausea and vomiting.

• Diarrhea.

• Stomach pain.

• Sore throat.

• Weakness.

• Swelling in feet and ankles.

• Anxiety.

• Ambiguous vaginal bleeding.

• Insomnia (sleepless nights).

• Bone and joint pain.

Some serious Fulvestrant side effects are:

• Shortness of breath.

• Pain in the chest.

• Burning sensation on urination.

• Pale eyes and skin.

• Swelling of the lips, including the tongue, face, and throat.

• Numbness in the legs.

• Rashes.

Also, various other side effects are associated with Fulvestrant medication. If any side effects are noticed, report them to the doctor immediately.

Dietary Alterations:

There is no specific dietary alteration needed when you are on Fulvestrant unless your doctor advises changes. Patients can continue to have a regular, healthy, and balanced diet.

What Should Be Done if You Forget a Dose?

If you missed the scheduled appointment for the dose, inform your doctor as early as possible.

What Should Be Done in Case of Fulvestrant Overdose?

In case of any overdose, reach out to the poison control helpline. It is advised to call the emergency number immediately in case a patient has collapsed or is experiencing breathlessness.

How to Store Fulvestrant?

Fulvestrant should ideally be stored at a temperature of two to eight degrees Celsius. It should be stored in its original container until used. It should be kept away from sunlight.

Avoid Self-Prescription:

The medicine should be used strictly under the doctor's prescription and supervision. After recording a thorough history, presenting symptoms, and performing confirmatory diagnostic scans for the condition, the doctor will prescribe the appropriate medication with the required doses and dosing schedule based on the diagnosis and examination.

Staying On Fulvestrant

• Take the Fulvestrant in the doses and frequency specified by the doctor. Do not miss any Fulvestrant injection schedule provided by the doctor.

• If any dose is missed, inform the doctor as soon as possible.

• Fulvestrant has proven to decrease the progression of cancer within 21 months of medication, even in the advanced stages.

• In case any side effects are noticed, inform the doctor immediately.

• Keep track of any improvement in symptoms after starting the medications and share it with your doctor during follow-up visits.

• Always inform your doctor if any progression or worsening of symptoms is observed.

For Doctors:

Indications:

The drug Fulvestrant is indicated in patients with postmenopausal breast cancer.

Pharmacology:

Mechanism of Action:

Women with post-menopausal breast cancer are estrogen receptor (ER) positive due to a sudden surge of estrogen levels in the body. The drug Fulvestrant acts by binding to these estrogen receptors and thereby blocking or degrading them, which is driving tumor growth.

Pharmacodynamics:

Fulvestrant medication has shown a reduction in the estrogen receptors with increasing doses in the patient after the medication is started. It has also shown a decrease in the expression of estrogen-regulating proteins after administration of Fulvestrant at increasing doses.

Chemical Taxonomy:

• Kingdom - Organic compound

• Superclass - Lipid and lipid-like molecules

• Class - Steroids and steroid derivatives

• Subclass - Estrane steroids

• Direct Parent - Estrogen and derivatives

Ingredients:

Active Ingredient: The only active ingredient is Fulvestrant.

Inactive Ingredients:

• Alcohol.

• Benzyl alcohol.

• Castor oil.

• Benzyl benzoate.

Absorption:

• Fulvestrant is observed slowly.

• The maximum plasma concentration peaks after seven days.

Distribution:

• Fulvestrant steady-state volume is around three to five L/kg (liters per kilogram).

• Fulvestrant has 99 percent binding efficiency to plasma proteins or lipoprotein particles.

Metabolism:

• Fulvestrant is metabolized by oxidation, hydroxylation, and glucuronidation to form less active metabolites.

Elimination:

• The total plasma clearance rate is 226 mL/min.

• The half-life of Fulvestrant is around 40 days.

Toxicity:

• No mutagenic or overdose clinical experience has been reported yet, based on the clinical trials of Fulvestrant.

Warnings and Precautions:

• With appropriate caution, Fulvestrant can be administered to patients with bleeding disorders or those receiving anticoagulant therapy.

• In a few patients, hepatic (liver) impairment was observed, so drugs are prescribed at a minimal dose of 250 mg for these patients.

• Fulvestrant is toxic to the fetus, so it is advised not to become pregnant while on medication.

Doses and Forms:

• Fulvestrant is administered intramuscularly.

• Fulvestrant is available as a clear, colorless, viscous liquid.

• Fulvestrant is available in doses of 250 mg per 5 mL vial.

Administration of the Drug:

Fulvestrant is administered intramuscularly once every two weeks on days 1, 15, and 29. After that, it is administered once a month.

Who Should Not Use Fulvestrant?

Fulvestrant is contraindicated in patients with allergic reactions to the drug (hypersensitivity).

Drug Interactions:

There is no known drug interaction of Fulvestrant reported yet.

Other Specifications:

Fulvestrant in Pregnant and Lactating Women:

• Fulvestrant has harmful effects on the fetus, so it is advised not to become pregnant while on medication and to inform the doctor prior to the condition.

• The side effects of the drug on the fetus in the lactating mother are not yet known. As many drugs are excreted in the milk, the use of Fulvestrant in a lactating mother is yet to be known.

Fulvestrant in Pediatric Patients:

There were a few adverse effects, like abnormal vaginal bleeding, redness and swelling around the injection area, increased heart rate, and hot flush, reported in the clinical trials conducted in pediatric patients.

Fulvestrant in a Patient With Renal Impairment:

The renal clearance of Fulvestrant is very low. Studies on the use of Fulvestrant in renal impairment have not yet been conducted.

Fulvestrant in a Patient With Hepatic Impairment:

Fulvestrant is mostly metabolized by the liver. So, safety and precautionary doses of 250 mg are indicated in patients with mild liver impairment.